The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
Their effect on muscle fibers and the tendency to cause fatigue brings up the topic of exercise and whether statins make it more difficult to execute a work-out routine. There are anecdotes about patients who think statins harm their athletic performance, but formal establishment of an effect is not so clear . A recently published study showed that rats given statins were not able to run as far as rats without the drug. Analysis of the muscle showed animals on the medicine had less glycogen and there was evidence of mitochondrial damage. Mitochondria are the parts of the cells that burn fuel for energy. If statin use makes exercise more difficult and less fun, it could inadvertently lead patients to become more sedentary, which is the opposite of what is desired. Increasing concerns about muscle-related adverse events are leading to the idea that lower doses of statins should be prescribed than current practice.
In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke(218/2365, % vs. 274/2366, %) and increased the incidence of hemorrhagic stroke (55/2365, % vs. 33/2366, %)compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17LIPITOR vs. 18placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) LIPITOR (4%) placebo].